Pasithea Therapeutics Corp.

KTTA Healthcare Biotechnology

In the quarter to June 2026, EPS grew 75.8% and free cash flow fell 21.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.42 0.01 +2.44%
Market cap
$13.7M
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
n/a
Altman Z
2.97
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
4.02 11.35 35.40 26.25
Net Debt/EBITDA
1.44 5.47 10.70 8.24
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.39) (0.77) (0.20) (0.15)
Book value per Share
1.64 7.85 2.25 1.55
Free Cash Flow
(2.89) (5.39) (4.79) (4.71)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates